vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
31.97
+2.57 (8.74%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Company Description
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases.
Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program.
vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
vTv Therapeutics Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 30, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Paul Sekhri |
Contact Details
Address: 3980 Premier Drive, Suite 310 High Point, North Carolina 27265 United States | |
| Phone | 336 841 0300 |
| Website | vtvtherapeutics.com |
Stock Details
| Ticker Symbol | VTVT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001641489 |
| CUSIP Number | 918385105 |
| ISIN Number | US9183852048 |
| Employer ID | 47-3916571 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul J. Sekhri | Chief Executive Officer, President and Chairman of the Board |
| Dr. Michael Steven Tung M.B.A., M.D. | Executive Vice President and Chief Financial Officer |
| Barry K. Brown | Chief Accounting Officer |
| Dr. Carmen Valcarce Ph.D. | Chief Scientific Officer and Executive Vice President |
| Elizabeth M. Keiley | Executive Vice President and General Counsel |
| Richard S. Nelson | Executive Vice President of Corporate Development and Director |
| Dr. Thomas Strack M.D., Ph.D. | Chief Medical Officer |
| Martin Lafontaine | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2026 | SCHEDULE 13G/A | Filing |
| Mar 27, 2026 | SCHEDULE 13G | Filing |
| Mar 10, 2026 | 8-K | Current Report |
| Mar 10, 2026 | 8-K | Current Report |
| Mar 10, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 2, 2026 | 8-K | Current Report |
| Dec 19, 2025 | 8-K | Current Report |
| Dec 9, 2025 | SCHEDULE 13D/A | Filing |